LSD-Assisted Psychotherapy in Patients with Terminal Cancer
The DOI matches its Crossref record.
Abstract
The paper describes the results of a clinical study exploring the potential of a complex psychotherapeutic program utilizing psychedelic compounds to alleviate the emotional and physical suffering of cancer patients. A total of 60 cancer patients participated in this experimental study. In 44 of these patients, LSD (200-500 p%per os) was administered as an adjunct to psychotherapy; in 19 patients, a new psychedelic compound, dipropyltryptamine (DPT) was administered (60-105 mg i.m.). Three of these patients received both LSD and DPT administered on different sessions. The therapeutic results were assessed by means of a rating scale reflecting the degree of the patients’ depression, psychological isolation, anxiety, difficulty in management, fear of death, and pain. The ratings were done by attending physicians, nurses, family members, LSD therapists and cotherapists, and independent raters. In addition, the amount of narcotics required in the management of the patient was measured before and after the psychedelic sessions. Systematic rating was carried out in a group of 31 cancer patients treated by LSD. The comparison of the means of individual ratings from pre- to posttreatment showed significant improvement in all the measured parameters for most of the raters. There was a definite reduction of the narcotic medication; it did not, however, reach the level of statistical significance. The pre- to post-treatment comparison of the global indexes used as gross indicators of the degree of emotional and physical distress, indicated that approximately 29 % of the patients showed dramatic improvement, and another 41.9 % moderate improvement, with 22.6 % essentially unchanged. In 6.4 % of the patients, global indexes showed a decrement in the posttherapy ratings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Post-treatment, patients showed 'dramatic improvement' (29%) and 'moderate improvement' (42%), or remained 'essentially unchanged' (29%).”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Grof et al., 1973
In the citing paper
“No serious adverse effects were reported.”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Grof et al., 1973
In the citing paper
“Overall, improvements were reported on anxiety, depression, and social isolation.”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Grof et al., 1973
In the citing paper
“Additionally, while we found some qualitative studies detailing patient experiences with classical psychedelics (Grof et al., 1973;Agin-Liebes et al., 2020;Belser et al., 2017), no qualitative studies on ketamine treatment in terminally ill patients were encountered in the literature.”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Grof et al., 1973
Citations
Cites
Still being checked.
Cited by
Items 101–200 of 208
Schifano, F., Napoletano, F., Chiappini, S., Orsolini, L., Guirguis, A., Corkery, J., Bonaccorso, S., Ricciardi, A., Scherbaum, N., & Vento, A. E. (2019) · Current Addiction Reports · doi:10.1007/s40429-019-00249-z · Cited by 20
Psycho-existential distress in cancer patients: A return to “entheogens”
Blinderman, C. D. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675761 · Cited by 17
Sicignano, D. J., Caroti, K. S., Hernández, A. V., & White, C. M. (2023) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000998 · Cited by 21
Pilozzi, A. R., Foster, S. L., Mischoulon, D., Fava, M., & Huang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512513 · Cited by 17
Psychedelic drugs in the treatment of anxiety, depression and addiction
Kvam, T.-M., Stewart, L. H., & Andreassen, O. A. (2018) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.17.1110 · Cited by 20
Some Compounds With Hallucinogenic Activity
Fanchamps, A. (1978) · Springer eBooks · doi:10.1007/978-3-642-66775-6_8 · Cited by 15
Psychological interventions in the treatment of cancer
Feinstein, A. (1983) · Clinical Psychology Review · doi:10.1016/0272-7358(83)90002-8 · Cited by 15
The concept of spirituality in palliative care: an alternative view
Paley, J. (2008) · International Journal of Palliative Nursing · doi:10.12968/ijpn.2008.14.9.31125 · Cited by 14
Stewart, B., Dean, J. G., Koek, A. Y., Chua, J. P., Wabl, R., Martin, K., Davoodian, N., Becker, C. J., Himedan, M., Kim, A., et al. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.688 · Cited by 16
Study protocol for “Psilocybin in patients with fibromyalgia: brain biomarkers of action”
Bornemann, J., Close, J. B., Ahmad, K., Barba, T., Godfrey, K., Macdonald, L., Erritzøe, D., Nutt, D. J., & Carhart-Harris, R. L. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1320780 · Cited by 16
Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management
Strand, N. H., Whitney, M. A., Johnson, B. W., Dunn, T., Attanti, S., Maloney, J. A., Misra, L., Gomez, D., Viswanath, O., Emami, E., et al. (2025) · Current Pain and Headache Reports · doi:10.1007/s11916-024-01353-0 · Cited by 15
Schuman, H. D. M., Savard, C., Mina, R., Barkova, S., Conradi, H. S. W., Deleemans, J. M., & Carlson, L. E. (2025) · Current Oncology · doi:10.3390/curroncol32070380 · Cited by 14
King, F., & Hammond, R. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20200047 · Cited by 14
Humanistic Psychology, Psychedelics, and the Transpersonal Vision
Grob, C. S., & Bossis, A. P. (2017) · Journal of Humanistic Psychology · doi:10.1177/0022167817715960 · Cited by 13
The role of psychedelics in palliative care reconsidered: A case for psilocybin
Kelmendi, B., Corlett, P. R., Ranganathan, M., D’Souza, C., & Krystal, J. H. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675781 · Cited by 11
Sholevar, R., Peteet, J. R., Sanders, J. J., & Beaussant, Y. (2023) · Palliative & Supportive Care · doi:10.1017/s1478951523001475 · Cited by 10
Wells, A., Muthukumaraswamy, A. P. S., Morunga, E., Evans, W., Cavadino, A., Bansal, M., Lawrence, N. J., Ashley, A., Hoeh, N. R., Sundram, F., et al. (2024) · Pilot and Feasibility Studies · doi:10.1186/s40814-024-01449-9 · Cited by 12
Weleff, J., Nunes, J. C., Costa, G. P. A., Sofuoglu, M., MacLean, R. R., & Aquino, J. P. D. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16045 · Cited by 15
Thal, S. B., Engel, L. B., & Bright, S. J. (2022) · Addiction Research & Theory · doi:10.1080/16066359.2022.2065268 · Cited by 10
Classic psychedelics do not affect T cell and monocyte immune responses
Rudin, D., Areesanan, A., Liechti, M. E., & Gründemann, C. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1042440 · Cited by 13
d-Lysergic acid diethylamide has major potential as a cognitive enhancerPreprint
da Silva, F. A. C., Ornelas, I. M., Marcos, E., Goto‐Silva, L., Nascimento, J. M., Ruschi, S., Salerno, J. A., Karmirian, K., Costa, M., Sequerra, E. B., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/866814 · Cited by 10
LSD use in the United States: Examining user demographics and their evolution from 2015–2019
Weleff, J., Anand, A., Dewey, E. N., & Barnett, B. S. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00309 · Cited by 12
Grob, C. S., Bossis, A. P., & Griffiths, R. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-85702-8_5 · Cited by 11
de Oliveira, D. S., Fontenele, R., Weleff, J., Sofuoglu, M., & Aquino, J. P. D. (2023) · International Review of Psychiatry · doi:10.1080/09540261.2023.2229430 · Cited by 9
Psychotropic Drugs in Terminally Ill Patients: A Review of the Clinical and Research Literature
Templer, D. I., Arikawa, H., & Gariety, P. C. (2004) · OMEGA - Journal of Death and Dying · doi:10.2190/9v5j-fg82-qrrn-uf87 · Cited by 9
Nichols, D. E. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0458-4 · Cited by 11
Gregory, N. S., Girard, T. E., Ram, A., Casey, A. B., Malenka, R. C., Tawfik, V. L., & Heifets, B. D. (2026) · Nature Communications · doi:10.1038/s41467-026-68763-z · Cited by 13
Korman, B. A. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00246 · Cited by 7
Positive Psychology and Buddhism
Segall, S. Z., & Kristeller, J. L. (2022) · Springer eBooks · doi:10.1007/978-3-031-10274-5_14 · Cited by 15
Fortwengel, G. (2003) · KARGER eBooks · doi:10.1159/000074701 · Cited by 7
Belitzky, E., Carvalho, L. V. R., Taylor, M. V., Naranjo-Ortiz, C., Baum, L. V. M., Fiellin, D. A., & Lustberg, M. B. (2025) · Cancer Medicine · doi:10.1002/cam4.70586 · Cited by 9
Jones, J. L. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1565852 · Cited by 10
Adapting psychedelic medicine for headache and chronic pain disorders
Schindler, E. A. D., & Hendricks, P. S. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2246655 · Cited by 9
The therapeutic potential of psychedelic substances in Hospice and Palliative Care
Garcia, A. C. M., & Maia, L. O. (2022) · Progress in Palliative Care · doi:10.1080/09699260.2022.2001140 · Cited by 7
Vollebregt, R., Storm, A. E. M., Lucassen, P. J., & Somers, M. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106529 · Cited by 11
Pilot study of psilocybin in patients with post-treatment lyme disease
Garcia‐Romeu, A., Naudé, G. P., Rebman, A. W., So, S., Yaffe, A., Geithner, I., Kozero, E. A., Yang, T., Soloski, M. J., & Aucott, J. N. (2026) · Scientific Reports · doi:10.1038/s41598-026-38091-9 · Cited by 6
Wang, J. R., Araque, S. J. M., Micciche, G., McMillan, A., Coughlin, E. C., Mattiola, R., English, D. P.-G., & Kaliebe, K. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1301960 · Cited by 11
Three cases of near death experience. Is it physiology, physics or philosophy?
Purkayastha, M., & Mukherjee, K. K. (2012) · Annals of Neurosciences · doi:10.5214/ans.0972.7531.190303 · Cited by 12
Abramsky-Sze, S., Marseille, E. A., Matzopoulos, R., Morlock, R., & Lerer, L. B. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1508811 · Cited by 5
Psychedelic therapy and cultural humility
Gearin, A. K., Docherty, J., Sun, X., Cheung, E. H.-L., & Tanuseputro, P. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03913-x · Cited by 4
Treatment of neuropathic pain with repeated low-dose MDMA: a case report
Gasser, P., Liechti, M. E., & Holze, F. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1513022 · Cited by 6
Psychedelics for the treatment of end-of-life distress in patients with a life-threatening disease
Tap, S. C., Bostoen, T., Breeksema, J. J., & Schoevers, R. A. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.03.001 · Cited by 4
Walt, J. V. D., & Parker, R. (2023) · South African Medical Journal · doi:10.7196/samj.2023.v113i11.814 · Cited by 5
D-Lysergic Acid Diethylamide (LSD) Investigator's Brochure
Jerome, L. (2008) · Cited by 6
Chaplains in Psychedelic Assisted Therapy: Rationale and Competencies
Lewis, S. P., Clark‐Soles, J., Mayorga, O., Sawyer, S. K., Slavet, E., Vidt, B. J., Shanti, S., Wiggins, R., Willis, K., Frey, J., et al. (2026) · Journal of Religion and Health · doi:10.1007/s10943-026-02591-9 · Cited by 4
Gold, N. D., Podrebarac, S. K., White, L. A., Marini, C., Simon, N. M., Mittelman, M. S., Ross, S., Bogenschutz, M. P., & Petridis, P. D. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2022.0011 · Cited by 3
Emmerich, N. (2024) · Neuroethics · doi:10.1007/s12152-024-09571-4 · Cited by 3
Psychedelics as novel therapeutic agents for chronic pain: mechanisms and future perspectives
Yasin, B., Mehta, S. M., Tewfik, G., & Bekker, A. (2024) · Exploration of neuroscience · doi:10.37349/en.2024.00058 · Cited by 4
Therapeutic Use of Psychedelics for Mental Disorders: A Systematized Review
Alyahya, N. M., & Saleem, E. A. A. (2024) · Journal of Nature and Science of Medicine · doi:10.4103/jnsm.jnsm_76_24 · Cited by 6
Hendricks, P. S., & Grob, C. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-32672-6_14 · Cited by 3
Chan, R. H. A., & Mendelson, J. E. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-418679-8.00017-4 · Cited by 4
Halpern, J. H., Suzuki, J., Huertas, P. E., & Passie, T. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0338-9_54 · Cited by 3
A scoping review of the effects of serotonergic psychedelics on attitudes towards death
Barr, N. N. T., Giese, K. J., & Moreton, S. G. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06787-x · Cited by 3
Kratina, S., Strıke, C., Schwartz, R. D., Nayfeh, A., Jopling, S. A., Lo, C., & Rush, B. R. (2025) · Social Science & Medicine · doi:10.1016/j.socscimed.2025.118536 · Cited by 2
Varela, Y. M., Tavares, V. D. D. O., Delgado, L. M., de Faria, H. A. T., Menezes, L. Q., Almeida, R. M., Agrícola, P. M. D., de Carvalho, B. S., Bienemann, B., Falchi-Carvalho, M., et al. (2026) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02188-5 · Cited by 1
de Sousa, P. C. M., de Sousa, I. N. A., Leite, L. L. L., Oliveira, A. L. O., Souza, K. A. D. S., Soares, J. D. S., Viana, M. D. R., & do Amaral, M. P. D. M. (2021) · Research Society and Development · doi:10.33448/rsd-v10i4.14251 · Cited by 3
Steinberg, M. I., Rosenberg, P., & Garcia‐Romeu, A. (2023) · Current Geriatrics Reports · doi:10.1007/s13670-023-00395-3 · Cited by 3
Barco, J. A. V., & Garcia, A. C. M. (2025) · Progress in Palliative Care · doi:10.1080/09699260.2025.2484066 · Cited by 2
Garrity, P. S., Danforth, A. L., Anderson, B. T., & Thompson, J. M. (2025) · Journal of Health Service Psychology · doi:10.1007/s42843-025-00145-3 · Cited by 2
Psilocybin as an alternative medicine for patients suffering from depression
Dydak, K., Śliwińska‐Mossoń, M., & Milnerowicz, H. (2016) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2016.0023 · Cited by 2
Lysergic Acid Diethylamide as an Analgesic Agent in Patients with Terminal Illnesses
Das, S., & Maiti, T. (2019) · Pain Management · doi:10.2217/pmt-2019-0043 · Cited by 2
Case Report: Resolution of Rheumatoid Arthritis in a Patient Consuming Psilocybin Mushrooms
Lin, D. S. (2020) · Journal of Healthcare · doi:10.36959/569/456 · Cited by 2
Could Psychedelics Treat Neuropathic Chronic Pain?
(2023) · Neurological Sciences and Neurosurgery · doi:10.47275/2692-093x-130 · Cited by 1
Psilocybin based therapy for cancer related distress, a systematic review and meta analysis
Bahi, C. (2019) · arXiv (Cornell University) · doi:10.48550/arxiv.1910.05176 · Cited by 2
Jerome, L. (2007) · Cited by 2
Psilocybin has no immediate or persistent analgesic effect in acute and chronic mouse pain modelsPreprint
Gregory, N. S., Girard, T. E., Ram, A., Casey, A. B., Malenka, R. C., Tawfik, V. L., & Heifets, B. D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.06.663398 · Cited by 2
Turner, T., & Glue, P. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2024.0008 · Cited by 2
Radiation therapy patients’ interest in psychedelic-assisted therapy: results of a survey
Park, J., Banks, R., Munjal, A., Hanubal, K. S., Peterson, N., Harada, G., Hoyt, M. A., Healy, E. H., & Harris, J. P. (2025) · Radiation Oncology · doi:10.1186/s13014-025-02686-9 · Cited by 2
Jevtić, M. (2025) · Engrami · doi:10.5937/engrami47-57385 · Cited by 1
Cavarra, M., Hutten, N. R. P. W., Schepers, J., Mason, N. L., Theunissen, E. L., Liechti, M. E., Kuypers, K. P. C., Bonnelle, V., Feilding, A., & Ramaekers, J. G. (2025) · British Journal of Pain · doi:10.1177/20494637251371626 · Cited by 1
Psychological support in psychedelic-assisted therapy clinical trials: A systematic review
Brusky, B., M’Baïlara, K., Alla, F., & Barrault, M. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261424204 · Cited by 2
Deutsch, A., Contreras, L. E., Kratina, S., & Mayo, L. M. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261433836 · Cited by 1
Robinson, J., Wallace, N., Cassidy, E. K., Lake, S., & Lucas, P. (2026) · Contemporary Drug Problems · doi:10.1177/00914509261444382 · Cited by 1
MINOR ÉS MAJOR PSZICHEDELIKUS SZERFOGYASZTÁS ÉS A HALÁLSZORONGÁS ÖSSZEFÜGGÉSEI
Károli Gáspár Református Egyetem, P. I., Ocsovszky, Z., Popovics, J., & Károli Gáspár Református Egyetem, P. I. (2017) · Psychologia Hungarica Caroliensis · doi:10.12663/psyhung.5.2017.1.1 · Cited by 2
Lasch, A., Schweikert, T., Dora, E., Kolb, T., Schurig, H. L., & Walther, A. (2023) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2046-5202 · Cited by 1
Geschichte der Anwendung von Psychedelika
Herwig, U. (2024) · Nervenheilkunde · doi:10.1055/a-2306-6120 · Cited by 1
CURRENT STATE OF PSILOCYBIN-ASSISTED THERAPY IN MOOD DISORDERS
Kaiserman, A., Vanderijst, L., & Kornreich, C. (2024) · Psychiatria Danubina · doi:10.24869/psyd.2024.174 · Cited by 2
Best, G., Morunga, E., Wells, A., Allison, J., & Reynolds, L. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2397427 · Cited by 6
Arnaud, K. O. S. (2022) · doi:10.24972/ijts.2019.38.2.31 · Cited by 2
The metaphysical combat with death in the terminally ill and the psychedelic trail
Dutta, V. (2014) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.131326 · Cited by 1
THE PSYCHOLOGICAL AND SPIRITUAL CHALLENGES INHERENT IN DYING WELL
Feinstein, D. L. (2007) · Cited by 1
Time Foran RANZCP Committee for the Investigation of Psychedelic Therapies?
Morstyn, R. (1993) · Australasian Psychiatry · doi:10.3109/10398569309081343
Behavioral Pharmacology of Hallucinogens
Morrison, N. K. (1998) · Springer eBooks · doi:10.1007/978-1-4757-2913-9_15
Clues from Other Scientific Disciplines
Sears, R. W. (2016) · Palgrave Macmillan UK eBooks · doi:10.1057/978-1-137-56371-2_5
Juan, D. M., Castañeda, C. A., & Wolfson, P. E. (2014)
Have no fear: Heritable neural patterns offer new potential targets for treating anxiety disorders
Hunter, P. (2019) · EMBO Reports · doi:10.15252/embr.201947823
The therapeutical role of psychedelic drugs in treatment of mental disorders
Oprea, D. C., Epure, L., Chiriță, V., & Cantemir, A. (2021) · Bulletin of Integrative Psychiatry · doi:10.36219/bpi.2021.3.09
Psilocybin-Assisted Psychotherapy in Palliative Care
Ross, S., & Bossis, A. P. (2022) · Oxford University Press eBooks · doi:10.1093/med/9780197583838.003.0042
Tetem, J., Fischmann, T., & Möller, T. J. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/ztyxh
Looking for Ted: black trips, “psychedelic” humanism, and silence
Cordova, M. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1198371
Breeksema, J. J. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.912040905 · Cited by 1
Schaller, A., Bourquin, G., Araujo, I. A., & Ljuslin, M. (2023) · Revue internationale de soins palliatifs · doi:10.3917/inka.242.0098
Intact neurophysiological markers of death denial in ayahuasca veteransPreprint
Dor‐Ziderman, Y., david, J., & Berkovich‐Ohana, A. (2024) · doi:10.31219/osf.io/my9sd
Lasch, A., Schweikert, T., Dora, E., Kolb, T., Schurig, H. L., & Walther, A. (2025) · Nervenheilkunde · doi:10.1055/a-2517-1621
Wells, A., Muthukumaraswamy, A. P. S., Morunga, E., Evans, W., Cavadino, A., Bansal, M., Lawrence, N. J., Ashley, A., Hoeh, N. R., Sundram, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25210532
Wells, A., Muthukumaraswamy, A. P. S., Morunga, E., Evans, W., Cavadino, A., Bansal, M., Lawrence, N. J., Ashley, A., Hoeh, N. R., Sundram, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25210812
Rabinovitch, B. S., Silverman, N., Ji, D., Shizgal, D., Lewis, E. C., & Carlen, P. L. (2026) · Brain Research · doi:10.1016/j.brainres.2025.150142
da Silva, F. A., Avelar, R. S., Peixoto, B., Bacelar–Nicolau, L., Santos, F., Ribeiro, J. C., & Heitor, M. J. (2026) · Brain and Behavior · doi:10.1002/brb3.71164 · Cited by 1
Metadata
- Authors
- Grof, S., Goodman, L. E., Richards, W. A., & Kurland, A. A.
- ORCID
- Richards, W.A.
- Venue
- International Pharmacopsychiatry
- Publisher
- S. Karger AG
- Published
- 2017-08-11
- Volume
- 8
- Issue
- 3
- Pages
- 129-144
- ISSN
- 0020-8272 (ISSN-L)
- 2504-2580
- OpenAlex
- W173089895
- Cited by
- 209
- References
- 0
- Citations by year
- 2026: 17 · 2025: 18 · 2024: 22 · 2023: 22 · 2022: 19 · 2021: 15 · 2020: 13 · 2019: 9 · 2018: 10 · 2017: 4
- FWCI
- 12.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- International Pharmacopsychiatry (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Palliative and Oncologic Care
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- lysergic acid diethylamide, psychedelic therapy, terminal cancer, end-of-life care, depression, anxiety, psychological isolation, fear of death, pain management, emotional distress
- MeSH terms
- Adult, Aged, Anxiety, Attitude to Death, Clinical Trials as Topic, Depression, Female, Humans, Lysergic Acid Diethylamide, Male, Middle Aged, MMPI, Narcotics, Neoplasms, Palliative Care, Psychiatric Status Rating Scales, Psychotherapy, Terminal Care, Tryptamines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.